Daiichi Sankyo Company, Limited

4568

JP3475350009

Pharmaceuticals

Delayed Japan Exchange Other stock markets 09:30:00 2026-01-18 pm EST			5-day change	1st Jan Change
3,255.00 ^JPY	-1.63%		-8.05%	-2.78%

Jan. 13	TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer	CI
Jan. 12	Daiichi Sankyo Company, Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 01:30 PM

Japan's Corporate Unwind Fuels Record Year for Block Trades

Published on 12/10/2025 at 09:10 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Daiichi Sankyo Company, Limited

Jan. 13	TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer	CI
Jan. 12	Daiichi Sankyo Company, Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 01:30 PM
Jan. 07	Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for Nanflyta®? Commercialization in Central and Eastern Europe	CI
Jan. 05	Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2025.	CI
Jan. 02	Daiichi Sankyo to spend roughly 300 billion yen to set up production facilities for targeted cancer medicine, Nikkei reports	RE
Dec. 29	Cardiogeni swings to loss as Daiichi Sankyo deal drops away	AN
Dec. 28	Senhwa?s CX-5461 with Astrazeneca/Daiichi Sankyo?s ADC, Trastuzumab Deruxtecan in Phase 1b HER2+ and Breast Cancer Trial; NCI Submits FDA Application	CI
Dec. 24	Daiichi Sankyo Announces Approval of ENHERTU® in China as First HER2 Directed Medicine for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies	CI
Dec. 22	AstraZeneca Starts Phase 3 Post-Surgery Endometrial Cancer Trial	MT
Dec. 22	AstraZeneca, Daiichi Sankyo's Enhertu Gets Breakthrough Therapy Designation in the US	MT
Dec. 22	AstraZeneca says lung cancer trial fails to meet survival target	AN
Dec. 22	AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Granted Breakthrough Therapy Status in US	MT
Dec. 22	Harbour Energy makes USD3.2 billion US buy	AN
Dec. 22	Enhertu® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with Her2 Positive Early Breast Cancer	CI
Dec. 21	Daiichi Sankyo Company, Limited Destiny-Endometrial02 Phase 3 Trial of Enhertu Initiated as Adjuvant Therapy in Patients with Her2 Expressing Endometrial Cancer	CI
Dec. 19	Language in health research grants is changing under political pressure	RE
Dec. 18	Daiichi Sankyo, AstraZeneca apply for second EU approval for Datroway	AN
Dec. 18	Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy	CI
Dec. 16	AstraZeneca and Daiichi Sankyo's Enhertu approved as first-line therapy for HER2+ breast cancer
Dec. 16	AstraZeneca, Daiichi Sankyo Drug Gets U.S. Nod for Breast-Cancer Label Expansion	DJ
Dec. 16	AstraZeneca, Daiichi Sankyo's Enhertu Regimen Greenlit as First-line Breast Cancer Treatment in US	MT
Dec. 16	UK Stocks-Factors to watch on December 16	RE
Dec. 15	AstraZeneca, Daiichi Sankyo's Enhertu Combination Gets US Approval for Breast Cancer Treatment	MT
Dec. 15	Daiichi Sankyo Company, Limited - Special Call
Dec. 15	U.S. FDA Clears AstraZeneca, Daiichi Sankyo Breast Cancer Drug	MT

Chart Daiichi Sankyo Company, Limited

Duration

Period

4568: Dynamic Chart

Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.

Employees

19,765

Sector

Pharmaceuticals

Calendar

Jan. 29 - Q3 2025 Earnings Release

More about the company